avandia

Glaxo Faces First of Many Possible Avandia Trials

Did GlaxoSmithKline's blockbuster diabetes drug Avandia cause fatal heart attacks? The first federal trial of an Avandia lawsuit began this morning in Philidelphia. As many as 50,000 more lurk in the wings.

FDA Panel Votes to Keep Avandia on Market

GlaxoSmithKline's diabetes drug Avandia has been found to have increased heart attack risk compared to other similar medication. But a majority of the Food and Drug Administration's panel of outside experts have voted to keep the drug on the market -- though new restrictions are likely.

GlaxoSmithKline Settles 10,000 Avandia Lawsuits

GlaxoSmithKline, whose diabetes drug Avandia is undergoing a safety review by the FDA, has agreed to pay about $460 million to resolve about 10,000 lawsuits from users of the drug, which can allegedly cause heart attacks and strokes.

FDA Panel Scrutinizing Diabetes Drug Avandia

On Tuesday, the FDA will convene a panel of experts to discuss GlaxoSmithKline's type II diabetes drug Avandia. Once a blockbuster, sales of the drug have dropped by more than half since studies suggested it significantly increases risk for serious heart problems.

Avandia Linked to Heart Attacks in Two New Studies

GlaxoSmithKline's diabetes drug Avandia once again captured headlines Monday morning after two new studies linked it to heart attacks and other cardiovascular complications. The authors of the studies say the results should prompt the FDA to pull the drug from the market.

FDA May Halt Safety Study on Diabetes Drug Avandia

The FDA is considering halting a safety study on GlaxoSmithKline's diabetes drug Avandia, The Wall Street Journal reported Sunday. Previous studies have linked Avandia to an increased risk of heart attacks. The implication is a serious threat to the continued sale of Avandia in the U.S.